Literature DB >> 24449512

Genetic dysregulation in recurrent respiratory papillomatosis.

Regina Rodman1, Simukayi Mutasa, Crystal Dupuis, Heidi Spratt, Michael Underbrink.   

Abstract

OBJECTIVES/HYPOTHESIS: Recurrent respiratory papillomatosis (RRP) is a devastating disease, caused by infection of the upper aerodigestive tract with human papillomavirus types 6 and 11. There is no cure for RRP, and surgical removal is the mainstay of treatment. The purpose of this project was to compare genes of cell cycle, apoptosis, and inflammatory cytokines in laryngeal papilloma versus normal tissue for a better understanding of the molecular mechanisms of the disease to discover novel therapies. STUDY
DESIGN: Basic science research study.
METHODS: Papilloma tissue was obtained from patients requiring surgical debridement. For comparison, normal mucosa was obtained from the excised uvula of patients undergoing uvulopalatopharyngoplasty. Total RNA was extracted from both groups and then probed using customized reverse transcriptase real time polymerase chain reaction gene arrays.
RESULTS: The custom arrays examine expression of 84 separate genes within the cell cycle, apoptosis, and inflammatory cytokine pathways. Our findings based on 11 papilloma samples run in comparison to normal mucosa shows that the MCL-1 gene of the apoptosis pathway is significantly downregulated. cytokine genes IL1-A, IL-8, IL-18, and IL-31 are also significantly dysregulated.
CONCLUSIONS: Genes of cell cycle and apoptosis are generally upregulated and downregulated, respectively, as expected in papilloma tissue, with MCL-1 achieving significance when compared to normal tissue. The finding of particular interest is that inflammatory cytokine genes were significantly downregulated, including IL1-A, IL-18, and IL-31. This finding may explain why patients infected with the virus are unable to mediate a T-cell immune clearance of their disease.
© 2014 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Recurrent respiratory papillomatosis; apoptosis; cell cycle; cytokines respiratory papillomatosis; laryngeal papilloma; papillomavirus infections; recurrent juvenile laryngeal papilloma; upper aerodigestive tract infection

Mesh:

Year:  2014        PMID: 24449512      PMCID: PMC4107152          DOI: 10.1002/lary.24602

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  28 in total

1.  BLAT--the BLAST-like alignment tool.

Authors:  W James Kent
Journal:  Genome Res       Date:  2002-04       Impact factor: 9.043

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells.

Authors:  S J Lee; Y S Cho; M C Cho; J H Shim; K A Lee; K K Ko; Y K Choe; S N Park; T Hoshino; S Kim; C A Dinarello; D Y Yoon
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

4.  Down modulation of IL-18 expression by human papillomavirus type 16 E6 oncogene via binding to IL-18.

Authors:  Y S Cho; J W Kang; M Cho; C W Cho; S Lee; Y K Choe; Y Kim; I Choi; S N Park; S Kim; C A Dinarello; D Y Yoon
Journal:  FEBS Lett       Date:  2001-07-20       Impact factor: 4.124

Review 5.  Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins.

Authors:  Anna-Marija Helt; Denise A Galloway
Journal:  Carcinogenesis       Date:  2003-02       Impact factor: 4.944

6.  Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and T(H)1/T(H)2 cytokine imbalance.

Authors:  V R Bonagura; L Hatam; J DeVoti; F Zeng; B M Steinberg
Journal:  Clin Immunol       Date:  1999-12       Impact factor: 3.969

7.  The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome.

Authors:  Tansu Ulukavak Ciftci; Oguz Kokturk; Neslihan Bukan; Ayse Bilgihan
Journal:  Cytokine       Date:  2004-10-21       Impact factor: 3.861

8.  Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP).

Authors:  W Bonnez; H K Kashima; B Leventhal; P Mounts; R C Rose; R C Reichman; K V Shah
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

9.  Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers.

Authors:  L Gissmann; L Wolnik; H Ikenberg; U Koldovsky; H G Schnürch; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

10.  Human papillomavirus up-regulates MMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adenocarcinomas.

Authors:  Ming-Yuh Shiau; Li-Ching Fan; Shun-Chun Yang; Chang-Hui Tsao; Huei Lee; Ya-Wen Cheng; Li-Chuan Lai; Yih-Hsin Chang
Journal:  PLoS One       Date:  2013-01-21       Impact factor: 3.240

View more
  3 in total

1.  Expanded Basal Compartment and Disrupted Barrier in Vocal Fold Epithelium Infected with Mouse Papillomavirus MmuPV1.

Authors:  Renee E King; Ella T Ward-Shaw; Rong Hu; Paul F Lambert; Susan L Thibeault
Journal:  Viruses       Date:  2022-05-16       Impact factor: 5.818

2.  High-throughput screening identifies candidate drugs for the treatment of recurrent respiratory papillomatosis.

Authors:  Faris Alkhilaiwi; Siddartha Paul; Dan Zhou; Xiaohu Zhang; Feibai Wang; Nancy Palechor-Ceron; Kelli Wilson; Rajarshi Guha; Marc Ferrer; Nazaneen Grant; Craig Thomas; Richard Schlegel; Hang Yuan
Journal:  Papillomavirus Res       Date:  2019-08-22

3.  Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes.

Authors:  Cem Sievers; Yvette Robbins; Ke Bai; Xinping Yang; Paul E Clavijo; Jay Friedman; Andrew Sinkoe; Scott M Norberg; Christian Hinrichs; Carter Van Waes; Clint T Allen
Journal:  Commun Biol       Date:  2021-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.